A Phase I Study of OCV-501 in the Treatment of Patients With Acute Myeloid Leukemia.

Trial Profile

A Phase I Study of OCV-501 in the Treatment of Patients With Acute Myeloid Leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs OCV 501 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 29 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top